Results 11 to 20 of about 8,722 (208)

Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials.

PLoS ONE, 2021
BackgroundUncertainty underlies the effectiveness of somatostatin analogues for slowing the progression of polycystic kidney or liver disease.MethodsEligible studies included randomized controlled trials (RCTs) evaluating somatostatin analog as therapy ...
Tatsuya Suwabe, Francisco J Barrera, Rene Rodriguez-Gutierrez, Yoshifumi Ubara, Marie C Hogan   +4 more
doaj   +1 more source

A transplantable phosphorylation probe for direct assessment of G protein-coupled receptor activation. [PDF]

PLoS ONE, 2012
The newly developed multireceptor somatostatin analogs pasireotide (SOM230), octreotide and somatoprim (DG3173) have primarily been characterized according to their binding profiles.
Andrea Kliewer, Anika Mann, Aline Petrich, Florian Pöll, Stefan Schulz   +4 more
doaj   +1 more source

Study Protocol of the PreFiPS Study: Prevention of Postoperative Pancreatic Fistula by Somatostatin Compared With Octreotide, a Prospective Randomized Controlled Trial

Frontiers in Medicine, 2021
Background: Pancreatic fistula (PF), i. e., a failure of the pancreatic anastomosis or closure of the remnant pancreas after distal pancreatectomy, is one of the most feared complications after pancreatic surgery.
Elisabeth Hain, Alexandre Challine, Stylianos Tzedakis, Alexandru Mare, Alessandro Martinino, David Fuks, Mustapha Adham, Guillaume Piessen, Jean-Marc Regimbeau, Emmanuel Buc, Louise Barbier, Jean-Christophe Vaillant, Florence Jeune, Laurent Sulpice, Fabrice Muscari, Lilian Schwarz, Sophie Deguelte, Antonio Sa Cunha, Stephanie Truant, Bertrand Dousset, Alain Sauvanet, Sébastien Gaujoux   +21 more
doaj   +1 more source

Resistance to Somatostatin Analogs in Acromegaly [PDF]

Endocrine Reviews, 2010
Somatostatin analogs (SA) are widely used in acromegaly, either as first-line or adjuvant treatment after surgery. First-line treatment with these drugs is generally used in the patients with macroadenomas or in those with clinical conditions so severe as to prevent unsafe reactions during anesthesia.
Colao, Annamaria, Auriemma, Renata S., Lombardi, Gaetano, Pivonello, Rosario   +3 more
openaire   +4 more sources

DISSOCIATION OF BIOCHEMICAL AND TUMOR-SUPRESSIVE EFFECTS OF SOMATOSTATIN ANALOGS

Alʹmanah Kliničeskoj Mediciny, 2016
Normalization of the growth hormone and IGF-1 levels during somatostatin analogs treatment usually is a predictor of somatotropinoma volume reduction.
A. V. Dreval’, I. A. Ilovayskaya, Yu. G. Pokramovich, G. A. Stashuk, R. S. Tishenina   +4 more
doaj   +1 more source

18F-FDG and 68Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study

EJNMMI Research, 2018
Background Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin tumor. Currently, 18F-fluoro-deoxy-glucose (18F-FDG) PET/CT is the functional imaging modality of choice. Few data are available on the use of 68Ga-somatostatin analogs.
Silvia Taralli, Martina Sollini, Michele Milella, Germano Perotti, Angelina Filice, Massimo Menga, Annibale Versari, Vittoria Rufini   +7 more
doaj   +1 more source

Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma

Frontiers in Oncology, 2020
Somatostatin receptor (SSTR) 2, widely expressed in meningioma, is a G-protein-coupled receptor and can be activated by somatostatin or its synthetic analogs.
Wei Wu, Yunxiang Zhou, Yali Wang, Lihong Liu, Jianyao Lou, Yongchuan Deng, Peng Zhao, Anwen Shao   +7 more
doaj   +1 more source

A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide

Clinical Case Reports, 2021
Long‐acting somatostatin analogs, including lanreotide slow release (LAN‐SR) and octreotide long‐acting release (OCT‐LAR), can improve hypoglycemia in insulinoma. LAN‐SR may be more beneficial in some patients with insulinoma than OCT‐LAR.
Keiko Yamaoka, Shuichi Nagashima, Nobukazu Okada, Nagisa Sawayama, Shinsuke Saito, Manabu Takahashi, Kenta Okada, Kazuhiro Endo, Masaru Koizumi, Hideki Sasanuma, Ken Ebihara, Atsuko Kasajima, Noriyoshi Fukushima, Naohiro Sata, Shun Ishibashi   +14 more
doaj   +1 more source

Insights into Structure-Activity Relationships of Somatostatin Analogs Containing Mesitylalanine

Molecules, 2013
The non-natural amino acid mesitylalanine (2,4,6-trimethyl-L-phenylalanine; Msa) has an electron-richer and a more conformationally restricted side-chain than that of its natural phenylalanine counterpart.
Pablo Martín-Gago, Eric Aragón, Marc Gomez-Caminals, Jimena Fernández-Carneado, Rosario Ramón, Pau Martin-Malpartida, Xavier Verdaguer, Pilar López-Ruiz, Begoña Colás, María Alicia Cortes, Berta Ponsati, Maria J. Macias, Antoni Riera   +12 more
doaj   +1 more source

Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging

Diagnostics, 2023
Gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) is a heterogeneous and complex group of tumors that are often difficult to classify due to their heterogeneity and varying locations.
Daniel Vogele, Stefan A. Schmidt, Daniel Gnutzmann, Wolfgang M. Thaiss, Thomas J. Ettrich, Marko Kornmann, Meinrad Beer, Markus S. Juchems   +7 more
doaj   +1 more source